middle.news
Neurotech Advances NTI164 with Ethics Nod for Pivotal Phase 3 Autism Trial
9:44am on Monday 2nd of February, 2026 AEDT
•
Healthcare
Read Story
Neurotech Advances NTI164 with Ethics Nod for Pivotal Phase 3 Autism Trial
9:44am on Monday 2nd of February, 2026 AEDT
Key Points
Human Research Ethics Committee approval obtained for Phase 3 trial
Trial targets autism spectrum disorder Levels 2 and 3
Designed to support submissions to Australian TGA and US FDA
Led by Professor Michael Fahey with multiple clinical sites
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurotech International (ASX:NTI)
OPEN ARTICLE